Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NeurogesX, Inc.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.
Directly launching a drug in Europe is the most difficult path for US-based biopharma companies, many of which decide to out-license rights for that territory. But, for the right asset, it’s also the most rewarding. The authors review 11 years of EMA approvals to examine European entry strategies’ effects on company valuations.
Acorda Therapeutics paid NeurogesX $7.9 million up front for a commercial pain therapy and a late-stage, topical pain drug candidate – from which Acorda expects to derive the most value – as NeurogesX prepares to settle its debts and wind down its operations.
- Topical Delivery
- Drug Delivery